DexCom DXCM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 61.5%+2.1pp | 60.1%-0.4pp | 59%-2.7pp | 58.8%-4.0pp | 59.4%-3.4pp | |
| Operating margin | 21.4%+6.2pp | 19.6%+4.7pp | 17.2%+1.3pp | 16%-1.3pp | 15.3%-1.9pp | |
| Net margin | 19.3%+6.4pp | 17.9%+3.7pp | 16%-1.3pp | 13.3%-3.7pp | 12.9%-3.9pp | |
| EBITDA margin | 26.8%+6.1pp | 25%+4.7pp | 22.6%+1.4pp | 21.5%-1.1pp | 20.7%-1.6pp | |
| Free cash flow margin | 29.7%+15.8pp | 23.1%+7.5pp | 23.5%+10.0pp | 13.3%-3.6pp | 13.9%-1.5pp | |
| Returns | ||||||
| Return on equity | 35.6%+11.9pp | 34.5%+6.9pp | 30.6%-1.4pp | 22.8%-6.6pp | 23.7%-4.8pp | |
| Return on assets | 13.9%+5.8pp | 13%+4.0pp | 10.4%-0.1pp | 8.1%-1.7pp | 8.1%-2.6pp | |
| Return on invested capital | 45.9%+15.5pp | 38.6%+9.2pp | 46.3%+11.9pp | 31.3%-9.4pp | 30.4%-1.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.7×+0.1× | 0.7×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Inventory turnover | 3×0.0× | 3.2×+0.3× | 3.1×+0.3× | 3.1×+0.2× | 3×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.9×+0.4× | 1.9×+0.4× | 1.6×-0.9× | 1.5×-1.3× | 1.5×-1.4× | |
| Quick ratio | 1.6×+0.3× | 1.6×+0.3× | 1.4×-0.7× | 1.3×-1.1× | 1.3×-1.2× | |
| Cash ratio | 0.5×+0.2× | 0.4×+0.2× | 0.6×+0.2× | 0.4×-0.2× | 0.3×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0.1×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -0.8×+0.1× | -0.7×-0.1× | -1.7×-1.1× | -1.1×-0.2× | -0.9×-0.1× | |
| Per Share | ||||||
| Book value per share | $7.51+35.1% | $6.77+32.9% | $6.69+38.7% | $6.30+7.9% | $5.56+3.2% | |
| Valuation | ||||||
| Market capitalization | $24.17B-9.7% | $25.89B-14.8% | $26.39B-1.8% | $34.34B-23.8% | $26.78B-49.9% | |
| Enterprise value | $23.19B-10.8% | $25.12B-16.0% | $24.68B-6.5% | $33.31B-24.8% | $26.01B-50.7% | |
| Price / earnings | 26×-24.1× | 31×-21.8× | 36.6×-2.8× | 60.1×-7.5× | 50×-33.6× | |
| Price / sales | 5×-1.4× | 5.6×-2.0× | 5.8×-1.0× | 8×-3.5× | 6.5×-7.6× | |
| Price / book | 8.2×-3.6× | 9.4×-5.0× | 9.7×-3.9× | 13.3×-5.2× | 11.8×-12.0× | |
| EV / EBITDA | 17.9×-12.4× | 21.6×-15.0× | 24.1×-7.3× | 36.1×-13.9× | 30.3×-31.9× | |
| EV / sales | 4.8×-1.5× | 5.4×-2.0× | 5.5×-1.2× | 7.7×-3.5× | 6.3×-7.6× | |
| Free cash flow yield | 5.9%+3.8pp | 4.2%+2.1pp | 4%+2.0pp | 1.7%+0.2pp | 2.1%+1.1pp | |
| Earnings yield | 3.8%+1.9pp | 3.2%+1.3pp | 2.7%+0.2pp | 1.7%+0.2pp | 2%+0.8pp | |
| PEG ratio | 0.4×— | 0.7×-7.5× | 6.2×+5.8× | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are DexCom's profit margins?
- DexCom (DXCM) runs a 61.5% gross margin and a 21.4% operating margin, with a 19.3% net margin.
- Where do DexCom's ratios come from?
- Every ratio is computed from DexCom's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
